ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
The Food and Drug Administration (FDA) in the United States [...]
The results from the following study were presented at the [...]
The following article from Practice Update discusses the JAVELIN Renal [...]
The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr [...]
Results from the JAVELIN Renal 101 phase 3 study to [...]
A clinical trial looking at the combination of avelumab plus [...]
Safety results from a phase 1b dose-finding and dose expansion [...]
The immunotherapy drug avelumab (Bavencio) has been designated a breakthrough [...]
This article, published in UroToday this week, is a nice summary [...]